Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
about
Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000: a population-based retrospective studyEffectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World PerspectiveViral Infection in the Development and Progression of Pediatric Acute Respiratory Distress SyndromeDefining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart DiseaseRespiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review.Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infantsAdherence to Immunoprophylaxis Regimens for Respiratory Syncytial Virus Infection in Insured and Medicaid Populations.Reduced Dicer expression in the cord blood of infants admitted with severe respiratory syncytial virus disease.The economic burden of prematurity in Canada.Immunoprophylaxis of respiratory syncytial virus: global experience.A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.Lower respiratory tract illness and RSV prophylaxis in very premature infants.Palivizumab for preterm infants. Is it worth it?Epidemiology of respiratory syncytial virus infection in preterm infants.Matrix Metalloproteinase-9 Mediates RSV Infection in Vitro and in VivoRisk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics.A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study.Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio StudyPalivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).Modeling the Potential Impact of the 2014 American Academy of Pediatrics Respiratory Syncytial Virus Prophylaxis Guidance on Preterm Infant RSV Outcomes.Risk factors for severe respiratory syncytial virus lower respiratory tract infectionHospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidencePreventing respiratory syncitial virus bronchiolitis.Net cost of palivizumab for respiratory syncytial virus prophylaxis during the 1998/99 season in northern Alberta.Association of Age With Risk of Hospitalization for Respiratory Syncytial Virus in Preterm Infants With Chronic Lung Disease.Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan.Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina
P2860
Q24803938-C5BE3E29-3FD1-4A98-9738-A7C7A2110D47Q26830864-2C858084-38F1-44AE-9FCC-E81A16D5B59AQ28071857-1EA1CB2B-1F22-4895-B1A8-5F7968D407EEQ28072535-DF218E5C-AC09-4B2A-9470-F42884F2515BQ30251560-494D0213-649F-4D92-A578-C6F0FBFA77D0Q31047460-908081E3-8D9F-42D6-AFB1-0E8259F52391Q33705088-61AC2D36-4B9D-4EB8-9170-8AF1833E41C2Q33840252-3E45A701-71CB-41B5-A61E-F75E3B7BC31EQ33938677-B37ABCA4-055C-42F5-8AA9-4B752CD83F91Q34740842-734F90D6-394C-4D47-961A-0CF44FC8AB15Q34884984-AA2B4EE8-CB23-4903-A2EB-C89F14858E8AQ35279606-A5BBD2AE-97CF-42D1-A370-01A7946EB498Q35296973-E5320C27-C973-4BB8-9EB2-57458C56A655Q35673550-6E92BE86-F2C4-42D4-BA64-F0FAE03C1A62Q36076225-A6AAAC6D-895B-476C-B69B-F3E3A9C1B472Q36093377-FAA4BF03-8220-45FD-B87C-B58BDC4F634AQ36275397-71239F73-5CD7-4219-9146-B55813A463CAQ36376822-A973DC54-7715-4C2C-A13A-C9E10FC83ADCQ36676407-17802CD1-E061-4DEE-9407-969CDADD9BA1Q36837007-F9DAAE89-A70E-4214-969A-31104F85EB67Q37290618-44A5F2E7-D909-43C2-9B47-DF62745C7524Q37660572-F4F6CCEC-9999-457D-AA8E-C939F390F5A7Q40395412-8F0D89F5-B9D6-4BEA-A981-A8054BA4CC7AQ40412523-8BC2A02F-75A3-4885-A406-F1730F842646Q42023014-A3E5B4E3-3B8C-40AC-902E-B1DDB7A7E22AQ42345813-A924B1BA-3730-42EE-8C45-CEF1B68FCB2CQ42770223-F38079C9-5D90-451E-82BF-1D87167C988FQ42938609-F4D3FD16-EC33-4767-B9BE-B7ED3E387E60Q45323813-CBC4D8D2-E7A8-4E55-8C7D-7F54556BB3FAQ54215865-B2E87E4F-96DC-49AF-89D2-495AD9AC101FQ58806120-21E5A1BA-EA1A-434F-98CE-4CAF16132466
P2860
Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Respiratory syncytial virus an ...... c implications of prophylaxis.
@en
Respiratory syncytial virus an ...... c implications of prophylaxis.
@nl
type
label
Respiratory syncytial virus an ...... c implications of prophylaxis.
@en
Respiratory syncytial virus an ...... c implications of prophylaxis.
@nl
prefLabel
Respiratory syncytial virus an ...... c implications of prophylaxis.
@en
Respiratory syncytial virus an ...... c implications of prophylaxis.
@nl
P2093
P1433
P1476
Respiratory syncytial virus an ...... c implications of prophylaxis.
@en
P2093
Maniscalco WM
McConnochie KM
Stevens TP
P407
P577
2000-01-01T00:00:00Z